Solid Biosciences insider grant: 142.5K options, 71.25K RSUs disclosed
Rhea-AI Filing Summary
Jessie Hanrahan, identified as a Director and the company's Chief Regulatory Officer, acquired equity in Solid Biosciences Inc. (SLDB) on 08/14/2025. The filing reports an employee stock option to purchase 142,500 shares at a $6.17 exercise price and 71,250 restricted stock units (RSUs), each RSU representing a right to one share. Following the transactions Hanrahan beneficially owns 142,500 options and 71,250 RSUs. The awards were granted on the stated date and include vesting terms: 50% of the original RSU grant vests on the second anniversary of the grant date and 25% annually thereafter until the fourth anniversary. The form is signed by an attorney-in-fact on 08/18/2025.
Positive
- Material equity grant disclosed: Reporting person received 142,500 options and 71,250 RSUs, aligning executive incentives with shareholders
- Clear vesting schedule provided: RSUs vest 50% on the second anniversary and 25% annually thereafter, showing retention structure
Negative
- None.
Insights
TL;DR: Large equity awards were granted to a senior officer with multi-year vesting, indicating retention-focused compensation.
The awards to the Chief Regulatory Officer consist of a sizable stock option and RSU package totaling 213,750 equity instruments (142,500 options plus 71,250 RSUs). The RSU vesting schedule is explicitly retention-oriented: half vests on the second anniversary and the remainder vests over the next two years. The option exercise price of $6.17 is disclosed, and the option term extends through the expiration date shown. These elements are consistent with standard executive long-term incentive design to align management with shareholder value over multiple years. This filing appears to be a routine grant rather than a change-in-control or special one-time award.
TL;DR: Form 4 reports an insider acquisition of equity on 08/14/2025, properly disclosed and signed by attorney-in-fact.
The Form 4 shows acquisition transactions coded A for both an employee stock option (142,500 shares at $6.17) and restricted stock units (71,250 RSUs). Beneficial ownership amounts after the transaction are explicitly reported. The filing includes the reporting person’s relationship to the issuer and a signature date of 08/18/2025, satisfying basic Section 16 disclosure requirements. There are no corrective amendments or additional transactions reported. Based solely on the filing text, this is a standard, timely insider equity grant disclosure.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) | 142,500 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 71,250 | $0.00 | -- |
Footnotes (1)
- The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").
